First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20
Adenocarcinoma, Follicular
/ drug therapy
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antigens, CD20
/ metabolism
Antineoplastic Combined Chemotherapy Protocols
/ pharmacokinetics
Female
Follow-Up Studies
Humans
Immunoglobulin G
/ administration & dosage
Lymphoma, Non-Hodgkin
/ drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Prognosis
Rituximab
/ administration & dosage
Tissue Distribution
Tumor Necrosis Factor Receptor Superfamily, Member 9
/ agonists
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
17
10
2019
revised:
17
02
2020
accepted:
03
03
2020
pubmed:
8
3
2020
medline:
4
9
2021
entrez:
8
3
2020
Statut:
ppublish
Résumé
In this phase I study (NCT01307267), we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular lymphoma (FL) and other CD20 Primary objectives were to assess treatment safety and tolerability for estimating the MTD, using a modified time-to-event continual reassessment method, and selecting the recommended phase II dose (RP2D). Sixty-seven patients received utomilumab (0.03-10.0 mg/kg every 4 weeks) and rituximab (375 mg/m Utomilumab in combination with rituximab demonstrated clinical activity and a favorable safety profile in patients with CD20
Identifiants
pubmed: 32144134
pii: 1078-0432.CCR-19-2973
doi: 10.1158/1078-0432.CCR-19-2973
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antigens, CD20
0
Immunoglobulin G
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Rituximab
4F4X42SYQ6
utomilumab
6YY8O697VF
Banques de données
ClinicalTrials.gov
['NCT01307267']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2524-2534Informations de copyright
©2020 American Association for Cancer Research.